Open-label and uncontrolled clinical trial by multicenter for liver regenerative therapy for liver cirrhosis using autologous subcutaneous adipose tissue-derived regenerative(stem) cells to assess efficacy and safety

Open-label and uncontrolled clinical trial by multicenter for liver regenerative therapy for liver cirrhosis using autologous subcutaneous adipose tissue-derived regenerative(stem) cells to assess efficacy and safety - Clinical trial of liver regenerative therapy using autologous adipose tissue-derived regenerative cells

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022601

Enrollment

Registered

2016-07-01

Start date

2017-10-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

intrahepatic arterial administration of autologous adipose tissue derived regenerative (stem) cells (3.3x10^5 cells/Kg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Criteria defined in the clinical trial implementation protocol

Exclusion criteria

Exclusion criteria: Criteria defined in the clinical trial implementation protocol

Design outcomes

Primary

Measure	Time frame
serum albumin concentration, prothrombin activity, harmful event, malfunction	—

Countries

Japan

Contacts

Public ContactYoshio Sakai

Kanazawa University College of Medical, Pharmaceutical and Health Sciences

yoshios@m-kanazawa.jp076-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026